There is provided an influenza virus detection chip and a method for detecting influenza virus therewith. An influenza virus detection chip including: a graphene oxide film; a first pad disposed on one side of the graphene oxide film in a first direction; and a first electrode and a second electrode, connected to both ends of the graphene oxide film in a second direction perpendicular to the first direction, wherein a first monoclonal antibody with a fluorescent label is included in the first pad, and a second monoclonal antibody is included in the graphene oxide film, and wherein the fluorescent label includes a C═C—C═C conjugated double bond.

A method for evaluating a biological material for unassociated virus-size particles having a particular epitope uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent antibody stain.

Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk in a patient with a respiratory illness, the method comprising: a. obtaining a sample obtained from the patient; b. quantitatively measuring in the sample a polypeptide level of one or more biomarkers selected from: IL-6, CXCL8, IL-10, IL-IRA, IL-2, IL-4, IL-7, IL-9, IL-13, IL-17, IFN-g, IP-10, MCP-1, G-CSF, GM-CSF, FGF-basic, SCGF-β, GRO-α, MIP1-α, MIP1-β, CK-18, PDGF-bb, caspase 3, HMGB-1, TNF α, VEGF, sTNFR1 and sTREM1; and c. i) comparing the level of the one or more biomarkers in the sample with a control or cut-off level, wherein the differential level is indicative of patient outcome risk; or ii) using the polypeptide level of several of the biomarkers in combination, as inputs for an algebraic calculation or machine learning model of patient outcome risk.

Arrays comprising probes comprising probes from more than one influenza strain or subtype are provided. Methods of using the arrays, as well as kits and systems comprising the arrays are also provided.

A sample capture and testing system can include a primary receptacle for receiving a fluid sample, where the primary receptacle has a sensor for label-free detection of an analyte disposed at one side. The primary receptacle can be incorporated in a needle for in vivo capture and testing of a sample. The primary receptacle can be incorporated into a specimen container and used as part of a point of care device.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, the virus may partition into one or more phases. In some cases, a virus-binding moiety facilitates partitioning of the virus. The phases may be assayed to determine the virus based on, e.g., quantitative or qualitative assessments of the distribution of virus-binding and/or signaling moieties. The virus-binding moiety may be attached to particles that may form a complex around a virus. The complex may be detectable without a signaling moiety (e.g., as a color change) in some embodiments. In some cases, more than one virus may be determined. For example, a virus-binding moiety may substantially alter the partitioning behavior of one virus or complex, relative to another, by being selective for the first virus.

Arrays comprising probes comprising peptides from more than one flavivirus are provided. Methods of using the arrays, as well as kits and systems comprising the arrays are also provided.

The present invention provides a recombinant sequence information of a key host factor ANP32A/B which is necessary for the replication of influenza virus in a host. More specifically, the present invention relates to a 129-130 motif and a 149 site of the host factor ANP32A/B protein, which are key active sites for exerting its ability to promote the replication of influenza virus, and are also potential targeting sites of anti-influenza drugs.

A lateral flow assay device for detection of an analyte in a sample and a method of detection thereof is provided. A quantitative assay for detection of an analyte in a sample is provided. A conjugate is provided. A method of diagnosing COVID 19 in a patient is provided.

A method for evaluating a biological material for unassociated virus-size particles having a particular epitope uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent antibody stain.